Literature DB >> 17270457

Reconstructive surgery in active mitral valve endocarditis: feasibility, safety and durability.

Laurent de Kerchove1, Jean-Louis Vanoverschelde, Alain Poncelet, David Glineur, Jean Rubay, Francis Zech, Philippe Noirhomme, Gebrine El Khoury.   

Abstract

OBJECTIVE: To evaluate timing for surgery and management of complex valve lesions in patients with active mitral valve (MV) endocarditis. Results are based on 13 years of experience with MV repair in active endocarditis.
METHOD: Between 1993 and 2005, 81 patients were operated for active MV endocarditis, of which 63 (or 78%) had MV repair. For all patients, the median time between diagnosis and surgery was 10 days. Diverse surgical techniques were applied to restore MV competence. In 59% of the patients, pericardial patches, tricuspid autograft or partial MV homografts were used as leaflet substitutes. In addition, prosthetic rings were employed in 44% of the patients.
RESULTS: The overall operative mortality was 17.5%. However, considering only patients in preoperative NYHA class I or II, the operative mortality could be reduced to 4.8%. NYHA class > or =3, elevated age (above 70 years) and history of valvular were the three independent risks factors for early mortality in our multivariate analysis. The average follow-up time was 60+/-37 months. During this period, five late deaths occurred, two of which were cardiac-related. The overall 5- and 10-year survival rate was 73+/-12% and 69+/-13%, respectively. In hospital survivors, freedom from cardiac death after 5 and 10 years was 93+/-8%. Three early and five late MV reoperations occurred in seven patients, of them four could have MV re-repair. Only one endocarditis recurrence occurred after 4 months in a chronic haeamodialysed patient. Freedom from MV reoperation was 89+/-10% and 72+/-24% at 5 and 10 years, respectively. Ten-year freedom from MV replacement and from endocarditis recurrence were 95+/-5% and 98+/-1%, respectively. Annular abscesses and calcified or rheumatic MV disease were two independent risk factors associated with reoperation in our multivariate analysis. During the follow-up period, all patients were in NYHA class I or II; 89% of patients had mitral regurgitation grade < or =I, only 11% had grade II on transthoracic echocardiography.
CONCLUSION: Using diverse and advanced techniques of MV repair, a reparability rate of 80% can be reached among patients with active endocarditis. We demonstrate that a high level of safety and excellent durability of MV repair can be obtained even for complex repairs.

Entities:  

Mesh:

Year:  2007        PMID: 17270457     DOI: 10.1016/j.ejcts.2007.01.002

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  9 in total

1.  Cardiac complications of infective endocarditis.

Authors:  John R Ebright
Journal:  Curr Infect Dis Rep       Date:  2009-07       Impact factor: 3.725

2.  Reconstruction of anterior mitral leaflet using autologous pericardial patch combined with posterior leaflet sliding for active infective endocarditis.

Authors:  Satoshi Kimura; Yuta Yamaki; Masayoshi Umesue
Journal:  Gen Thorac Cardiovasc Surg       Date:  2013-04-24

3.  Repair for active infective atrioventricular valve endocarditis: 23-year single center experience.

Authors:  Michele Musci; Michael Hübler; Aref Amiri; Julia Stein; Susanne Kosky; Yuguo Weng; Miralem Pasic; Roland Hetzer
Journal:  Clin Res Cardiol       Date:  2011-06-25       Impact factor: 5.460

4.  A Case of Mitral Valve Endocarditis Complicated by Multiple Embolic Phenomena: Leaping from Adult Guidelines to Pediatric Critical Care Decisions.

Authors:  Tarif A Choudhury; Jonathan N Flyer; Henry M Ushay; George Ofori-Amanfo
Journal:  J Pediatr Intensive Care       Date:  2018-11-26

Review 5.  Infective endocarditis--prophylaxis, diagnostic criteria, and treatment.

Authors:  Nadja Westphal; Björn Plicht; Christoph Naber
Journal:  Dtsch Arztebl Int       Date:  2009-07-13       Impact factor: 5.594

6.  Should more patients be offered repair for mitral valve endocarditis? a single-centre 15-year experience.

Authors:  Clarissa Ng Yin Ling; David Bleetman; Soumik Pal; Hing Chi Kristie Leung; Habib Khan; Donald Whitaker; Olaf Wendler; Ranjit Deshpande; Max Baghai
Journal:  J Cardiothorac Surg       Date:  2022-09-30       Impact factor: 1.522

Review 7.  Biodegradable materials for surgical management of infective endocarditis: new solution or a dead end street?

Authors:  Patrick O Myers; Mustafa Cikirikcioglu; Afksendiyos Kalangos
Journal:  BMC Surg       Date:  2014-08-03       Impact factor: 2.102

8.  Inception of the 'endocarditis team' is associated with improved survival in patients with infective endocarditis who are managed medically: findings from a before-and-after study.

Authors:  Amit Kaura; Jonathan Byrne; Amanda Fife; Ranjit Deshpande; Max Baghai; Margaret Gunning; Donald Whitaker; Mark Monaghan; Philip A MacCarthy; Olaf Wendler; Rafal Dworakowski
Journal:  Open Heart       Date:  2017-12-27

9.  A structured approach to native mitral valve infective endocarditis: Is repair better than replacement?

Authors:  Rufin J Defauw; Anton Tomšič; Thomas J van Brakel; Nina Ajmone Marsan; Robert J M Klautz; Meindert Palmen
Journal:  Eur J Cardiothorac Surg       Date:  2020-09-01       Impact factor: 4.191

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.